StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research note issued to investors on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Up 13.9 %
NASDAQ:AKTX traded up $0.44 during midday trading on Tuesday, hitting $3.61. The company had a trading volume of 6,477 shares, compared to its average volume of 18,681. Akari Therapeutics has a 52-week low of $1.08 and a 52-week high of $5.20. The stock’s fifty day moving average price is $3.25 and its 200-day moving average price is $2.36.
Institutional Trading of Akari Therapeutics
An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC boosted its holdings in Akari Therapeutics, Plc (NASDAQ:AKTX – Free Report) by 48.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 87,628 shares of the biopharmaceutical company’s stock after purchasing an additional 28,511 shares during the period. Omnia Family Wealth LLC owned approximately 1.55% of Akari Therapeutics worth $273,000 at the end of the most recent reporting period. Institutional investors own 5.06% of the company’s stock.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Featured Articles
- Five stocks we like better than Akari Therapeutics
- What is a Special Dividend?
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Want to Profit on the Downtrend? Downtrends, Explained.
- MarketBeat Week in Review – 8/5 – 8/9
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.